Abbott Laboratories announced that it will acquire Exact Sciences Corporation for $105 per share, valuing Exact Sciences at approximately $21 billion in equity value. The transaction includes an enterprise value of $23 billion and a net debt assumption of about $1.8 billion, and the parties have agreed that the deal is expected to close on March 23, 2026.
The acquisition positions Abbott to enter the fast‑growing cancer screening and diagnostics market, adding Exact Sciences’ leading portfolio of products such as Cologuard, Oncotype DX, Oncodetect, and Cancerguard. The platform is expected to complement Abbott’s existing diagnostics business and create a new high‑growth vertical that can accelerate early detection and treatment guidance across a broad patient population.
Financially, the deal is projected to add roughly $3 billion in incremental sales for Abbott in 2026, boosting the company’s sales growth by about 0.5%. The transaction will also dilute Abbott’s 2026 adjusted earnings per share by approximately $0.20, reflecting the premium paid for Exact Sciences’ equity and the associated debt assumption.
Exact Sciences reported Q4 2025 revenue of $878 million and a net loss of $86.0 million, or –$0.45 per diluted share. This loss is a significant increase from the $1.2 million net loss reported in Q4 2024, underscoring the company’s continued investment in research and development and expansion of its product pipeline.
Abbott’s own financials for the same period show a Q4 2025 adjusted diluted EPS of $1.50, up 12% year‑over‑year, and a full‑year 2025 adjusted diluted EPS of $5.15, up 10% year‑over‑year. Q4 2025 revenue reached $11.46 billion, a 4.4% increase from the prior year, indicating steady growth in Abbott’s core diagnostics and medical device segments.
Management emphasized the strategic fit of the transaction. Robert B. Ford, Chairman and CEO of Abbott, said, "Proactively shaping the portfolio to anticipate future medical needs while building long‑term shareholder value remains at the core of our strategic framework. The addition of Exact Sciences enhances Abbott’s growth profile and strengthens our leadership in diagnostics. This transaction brings a powerful new platform in cancer screening and diagnostics into Abbott, advancing our mission to make care more accessible and give people more control over their health." Kevin Conroy, Chairman and CEO of Exact Sciences, added, "Together with Abbott, we can reach more patients, advance earlier detection, and deliver answers that change lives."
Investors reacted to the premium offered and the strategic fit of the transaction. Analysts noted the significant upside potential for Abbott’s diagnostics portfolio and the opportunity to expand into a $60 billion U.S. cancer screening market, while also recognizing the premium’s impact on Exact Sciences’ shareholders, who now have a fixed exit price.
The announcement confirms that the acquisition will close on March 23, 2026, marking a key milestone in Abbott’s strategy to strengthen its diagnostics capabilities and expand its presence in the oncology market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.